For obtaining the full report please click here to contact us.

Recently, the therapeutic application of stem cells has been attracting attention worldwide. It’s seen from a growing number of clinical trials and research in this field together with the increase of companies providing medical services, products, devices in the field of stem cells. There is also a significant rise in the number of clinical application of stem cells and the advent of new treatments for chronic diseases are estimated to enhance the growth of the global stem cells market in the next few years.

The research showed that estimations of the global stem cell market size and growth range dramatically, mainly because of lack of a unified approach for the market scope assessment.

Segmented by-product, the stem cells market presently constitutes mainly adult stem cells as they help in repairing damaged tissues via cell division and offer advantages like ease of harvesting, high acceptance in the human body and effectiveness in tissue generation, minimal ethical issues, and long-term renewal property associated with stem cells utility. At the same time the use of embryonic stem cells for research and therapeutic purposes, though being with higher totipotency and indefinite lifespan, as compared to the adult stem, is restricted and prohibited in many countries throughout the world, due to some ethical constraints. As a result, 98% of clinical trials are conducted with adult stem cells.

Autologous stem cell therapy holds a slightly larger market in comparison with allogenic. The trend to move to allogeneic is strongly driven by the pharma industry which prefers one source for manufacturing multiple doses.

The drug discovery application dominates the market, in terms of revenue. North America generates the highest revenue and is expected to be the leading region globally, whereas the Asia Pacific market is also expected to witness significant market growth in the coming years.

The global mesenchymal stem cell (MSC) market share is dramatically smaller than the hematopoietic stem cell (HSC). While market shares of both grow with comparable pace, MSC, in particular, is experiencing a significant surge in clinical trials in the last years and in 2019 especially. This trend is even clearer considering the number of trials in the recruitment stage throughout the phases – in recent years, more trials are being conducted in MSC.

According to our analysis, the more mature HSC market will keep the growing trend until 2025 due to a significantly large number of started clinical trials. However, the analysis of the clinical trials shows that a majority of MSC involved trials are currently on recruitment stages and conducted mostly for Phase I, which suggests a potential for a higher growth rate of MSC market in the upcoming years.

In 2019 there seems to be a consolidation of both HSC and MSC to a similar number of clinical trials, due to significant growth of the MSC market. This suggests that the number of MSC clinical trials in the coming years will be higher than those in HSC.

MSC is a “younger” technology, full of potential and in the future can be used to treat more indications than HSC. MSC will be trialed for a broader number of indications, as the technology matures and the number of trials increases.

Asia is the region with the largest number of started MSC trials taking over 40% and showing permanent growth, while the USA share in the world MSC trials is growing within last 5 years demonstrating a leap in 2016 from 10% to 30% of worldwide trials. As for the HSC clinical trials arena, more than a half (almost 60%) of the clinical trials nowadays are started in the USA, around 17% – in Europe, and around 17% in Asia (mostly in China).

Comparing the data on market value forecast and clinical trials, we can suggest that the more mature HSC market will keep the growing trend until 2025. However, the analysis of the clinical trials shows that a majority of trials involving MSC are currently on recruitment stages and conducted mostly for Phase I, which suggests more growth potential in the years after 2025.

In the current technological and business environment, we expect that investment in MSC and related products can potentially boost growth, revenues, and profits even more than equivalent investments in HSC.

For obtaining the full report please click here to contact us.

Table of Contents

1. Executive Summary

2. Introduction

3. Stem cells market dynamics and trends by segments – product type, application, treatment type.

    3.1. By product type

        3.1.1. Adult stem cells

        3.1.2. Embryonic stem cells

    3.2. By treatment type

        3.2.1. Autologous stem cells

        3.2.2. Allogeneic stem cells

    3.3. Gene and cell manipulation

         3.3.1. CART-T

         3.3.2. CRISPR

         3.3.3 Exosomes

4. Current trends in hematopoietic and mesenchymal stem cells markets

5. Competitive landscape

    5.1. 300 companies’ profiles including major players and niche players

    5.2. Competitive analysis and intelligence analysis

Figures

Figure 1. Stem Cell Research Policies around the World

Figure 2. Number of clinical trials with adult and embryonic stem cells

Figure 3. Clinical trials with embryonic stem cells and adult stem cells in 2014-2018

Figure 4. Number of clinical trials with autologous and allogeneic stem cells

Figure 5. The estimated annual number of HCTs performed in the US

Figure 6. Annual Investment in the CAR-T Space from 2000 to Present

Figure 7. Number of initiated FDA clinical trials per year

Figure 8. HSC and MSC markets development trends, in US$ bln

Figure 9. Number of clinical trials with HSC, by phase

Figure 10. Number of clinical trials with MSC, by phase

Figure 11. Comparison of clinical trials started in 2018 and January-April 2019

Figure 12. MSC trials in the recruitment stage

Figure 13. HSC trials in the recruitment stage

Figure 14. Total trials in MSC and HSC

Figure 15. Aggregated number of clinical trials and conditions

Figure 16. Diversity ratio of indications by trial

Figure 17. Diversity ratio over time

Figure 18. MSC clinical trials distribution by regions by year, %

Figure 19. HSC clinical trials distribution by regions by year, %

To contact our analyst for a discussion on the findings, click Speak to Analyst.